June 10, 2025

New Tool May Identify Patients at High Risk of Developing RA

New criteria may aid in identifying patients with joint pain who are at high risk of developing rheumatoid arthritis, enabling earlier intervention and better trial recruitment.

Conexiant

June 02, 2025

Glycosylated IgG Disrupts Kidney Cell Metabolism: Study 

Children with lupus nephritis had altered IgG sugar chains that impaired kidney cell metabolism, and removing those sugars reversed the injury in lab tests.

Conexiant

June 02, 2025

Only 20% Account for 80% of Steroid Use: Study

In a UK-wide analysis of nearly 2 million patients, researchers found that “a fifth of patients receiving corticosteroids accounted for over 80% of oral and inhaled corticosteroid prescribing,” highlighting concentrated use and variable treatment persistence across formulations.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 23, 2025

New Inhaled Treprostinil Option Approved

Yutrepia represents an additional therapeutic option within the prostacyclin class for the management of PAH and PH-ILD.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Growth Disrupted in One-Third of JIA Patients, Study

In a study of 107 children with juvenile idiopathic arthritis, researchers found that one-third had growth or pubertal disturbances—often linked to disrupted hormone levels and longer disease duration.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

April 30, 2024

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

Conexiant